Published in Health Business Week, August 14th, 2009
Taxotere (up 10.7%). Further dynamism in the worldwide presence of
Plavix (up 9.6%) -- Growth of 18.4% for the Vaccines business excluding H5N1 contracts(2) -- Net sales growth of 5.4% in the U.S., 4.6% in Europe and 20.1% in
Emerging Markets -- Multaq : approved by the FDA on July 1, and launched in the United
States on July 28 2009 Results and Guidance -- 2009 second-quarter growth of adjusted EPS excluding selected items of
17.2% at constant exchange rates and 29.9% on a reported basis -- Strong cash flow from operating...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.